Peptide-Drug Conjugates: The Quiet Revolution in Targeted Cancer Therapy

Antibody-drug conjugates dominate targeted cancer therapy headlines — 15+ are FDA-approved, and deals like Pfizer's $43B Seagen acquisition and Gilead's $3.15B buyout of Tubulis have cemented ADCs as a premier oncology modality. A quieter parallel story has been unfolding alongside it: peptide-drug conjugates.

The structural difference is simple. Both platforms marry a targeting moiety, a linker, and a payload (cytotoxic drug or radioisotope). Where ADCs use a full antibody around 150 kDa, PDCs use a short peptide — often 2–5 kDa, sometimes cyclic or macrocyclic. That ~30x size reduction cascades into every aspect of the drug's behavior.

The advantages PDCs carry over ADCs are concrete. Tumor penetration is the biggest one. Antibodies bounce off the periphery of dense, hypoxic solid tumors; small peptides diffuse through them. This is why Lutathera works in neuroendocrine tumors that are notoriously fibrotic and stromal. Manufacturing economics are the second. PDCs are made via solid-phase peptide synthesis — homogeneous, reproducible, chemically characterized. ADCs require mammalian cell culture with drug-antibody ratio heterogeneity. Per-gram costs diverge by an order of magnitude. Immunogenicity is the third. No Fc-mediated effector functions, no anti-drug antibody concerns that plague some ADCs.

The main PDC liability is fast clearance. Naked peptides have half-lives of minutes to hours instead of days. This is why the first-generation commercial success for PDCs came from radioligand therapy, where you actually want fast clearance — the payload does its work before the peptide is excreted.

As of April 2026, two PDCs are FDA-approved, both from Novartis, and both radioligand therapies — peptides conjugated to lutetium-177, a beta-emitting radioisotope.

Lutathera (lutetium-177 dotatate) was approved in January 2018 for SSTR2-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It targets somatostatin receptor type 2, overexpressed in neuroendocrine tumors. In April 2024, the FDA expanded Lutathera's label to first-line therapy based on the NETTER-2 trial, which showed a median progression-free survival of 22.8 months vs 8.5 months with octreotide alone — a 72% reduction in risk of progression or death. Mayo Clinic's real-world data in bronchopulmonary NETs showed median PFS of 10.8 months and median overall survival of 35.6 months, validating the trial results outside of selected trial populations.

Pluvicto (lutetium-177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) was approved in March 2022 for metastatic castration-resistant prostate cancer (mCRPC) in post-taxane patients, based on the VISION trial. The bigger news came in March 2025: a label expansion to pre-taxane mCRPC based on the PSMAfore trial, which showed a 59% reduction in radiographic progression or death (median rPFS 11.6 vs 5.6 months). That single expansion tripled Pluvicto's eligible patient population. The commercial impact was immediate — Q2 2025 sales hit $454M (+22% quarter-over-quarter), new patient starts grew 60% QoQ, and community oncology centers now account for 58% of prescriptions. Analyst peak sales projections sit around $5B.

Novartis is already extending this playbook. The PSMAddition Phase 3 trial read out positive rPFS with a positive overall survival trend in metastatic hormone-sensitive prostate cancer (mHSPC), with filing planned for 2H 2026. If approved, it would be the first radioligand therapy for hormone-sensitive disease, expanding the addressable market again.

Not every PDC story has a happy ending. Pepaxto (melphalan flufenamide), developed by Oncopeptides, was FDA-approved in February 2021 for fourth-line-plus multiple myeloma based on the HORIZON study's 23.7% objective response rate. It used a lipophilic peptide carrier to deliver alkylating agent payloads to aminopeptidase-overexpressing tumor cells.

The confirmatory OCEAN trial didn't just fail to improve outcomes — it showed increased risk of death compared to pomalidomide. On February 23, 2024, the FDA issued its final decision to withdraw Pepaxto, marking the first use of the amended withdrawal procedures under FDORA 2022. Oncopeptides has since pivoted its platform focus to SPiKE, a small-polypeptide NK-cell engager approach, with lead candidate OPSP1.

The lesson: accelerated approval on ORR is conditional on confirmatory trial evidence. In a crowded therapeutic class like multiple myeloma, a PFS win is insufficient if overall survival trends against the drug. Future PDCs targeting high-mortality cancers with competitive standards of care will need to design confirmatory trials with realistic OS endpoints from the start.

Pepaxto remains approved at the EMA and MHRA, and ex-US sales drove Oncopeptides' Q3 2025 revenue up 174%. The asset isn't dead globally — it's just no longer available in the US.

The radioligand therapy market — the commercial home of PDCs today — is projected by industry analysts to grow from ~$2.6B in 2025 to somewhere between $4.8B (conservative) and $29.5B (bull case) by 2030-2034. The wide range reflects genuine uncertainty about supply chain scale-up and reimbursement, but nobody doubts the growth trajectory.

The current commercial drugs use lutetium-177, a beta-emitter with a 6.6-day half-life. Lu-177 is relatively easy to produce, has established supply chains, and delivers enough radiation damage per dose to shrink tumors with manageable kidney and bone marrow toxicity.

The next generation is alpha-emitters. Actinium-225 and lead-212 deliver dramatically more energy per decay (5-10x) across a much shorter path length (~100 μm vs ~1-2 mm for Lu-177), meaning more potent tumor kill with less collateral damage. The clinical data is compelling:

• Perspective Therapeutics presented AACR 2026 interim data for [212Pb]VMT-α-NET — a first-in-class Pb-212 alpha-emitter targeting SSTR2 in neuroendocrine tumors. The Phase 1/2a trial showed 43% confirmed ORR in Cohort 2 (10 of 23 patients), with 72% remaining progression-free. No dose-limiting toxicities. Safety across 64 treated patients was manageable.
• Molecular Partners' MP0712 is a 212Pb Radio-DARPin targeting DLL3 in small cell lung cancer — where DLL3 is expressed in >85% of tumors. First imaging and dosimetry data in patients was presented at TWC 2026; efficacy data is expected later in 2026.
• Novartis is developing Ac-PSMA-617 and next-gen Ac-PSMA-R2 in the Satisfaction Phase 1/2 trial, targeting both Pluvicto-naive and post-Pluvicto patients.

The alpha-emitter race is constrained by isotope supply. Global Ac-225 production sits in the tens of gigabequerels per year — enough for only a few thousand patient doses. Pb-212's 10.6-hour half-life enables point-of-use preparation but demands specialized logistics. Novartis's $1.75B acquisition of Mariana Oncology in May 2024 was largely a bet on solving this supply constraint at scale.

Emerging targets beyond SSTR2 and PSMA are broadening the addressable tumor universe: FAP (fibroblast activation protein, expressed in stroma of >90% of epithelial cancers), DLL3 (SCLC), and integrin αvβ6 (Lu-177-Therahexin reported first-in-human data in breast cancer in February 2026). FAPI-RGD dual-targeting constructs are showing superior tumor uptake in early studies.

Radioligands deliver payload by decay; cytotoxic PDCs deliver chemotherapy through cleavable linkers. Both approaches are crowding into the clinic.

Bicycle Therapeutics is the most prominent publicly-traded PDC-focused company. Its bicyclic peptide phage display platform produces constrained dual-loop peptides (~1.5–2 kDa) with antibody-like target affinity but small-molecule pharmacokinetics. Two drugs are deep in clinical development. Zelenectide pevedotin (BT8009, Nectin-4) showed 45% ORR as monotherapy in post-EV-naive metastatic urothelial cancer in Duravelo-1, and 65% ORR (5 CR, 8 PR) in first-line cisplatin-ineligible patients combined with pembrolizumab; Duravelo-2 Phase 2/3 is ongoing. Nuzefatide pevedotin (BT5528, EphA2) covered >150 patients in AACR 2026 data presented April 20; the company selected 8 mg/m² Q2W as the Phase 2 dose for second-line pancreatic ductal adenocarcinoma. A companion Ga-68-labeled EphA2 PET imaging agent presented the next day detected liver, bone, and lymph node metastases in 15 of 18 PDAC patients — potentially a patient-selection tool that tightens the therapeutic index.

Circle Pharma presented CID-078 — a first-in-class oral macrocyclic cyclin A/B RxL inhibitor — at the AACR 2026 plenary on April 19. Phase 1 dose-escalation data across 79 heavily pretreated patients showed confirmed responses in seventh-line RB1-altered pleomorphic sarcoma and fourth-line neuroendocrine tumor. Circle's pitch is that macrocyclic peptides can drug targets previously considered undruggable (RB-dysregulated cancers via cyclin A/B).

Sapience Therapeutics showed first Phase 2 data at AACR 2026 for ST316, a first-in-class β-catenin/BCL9 antagonist built on the SPEAR platform. Second-line colorectal cancer expansion showed no dose-limiting toxicities, no related SAEs, and significant knockdown of Wnt-related gene signatures in tumor cells. β-catenin had been considered functionally undruggable for decades.

PeptiDream, the Japanese PDC platform company, continues to rack up partnerships. Its PDPS (Peptide Discovery Platform System) uses mRNA display of genetically expanded libraries to screen trillions of macrocyclic peptides. Novartis added $180M to its deal in 2024; Janssen, Shionogi, and Genentech (specifically for peptide-radioisotope conjugates) are also active collaborators. On April 19, 2026, Asahi Kasei initiated a Phase 1 trial of AK1940, a PeptiDream-discovered macrocyclic TNFR1 antagonist for autoimmune disease — proof that the PDC format isn't limited to oncology.

Merck's enlicitide decanoate is worth watching separately. It's an oral macrocyclic peptide PCSK9 inhibitor — Phase 3 CORALreef AddOn data (March 2026) showed 64.6% LDL-C reduction at 8 weeks added to statins, outperforming bempedoic acid and ezetimibe. Merck received the FDA's Commissioner's National Priority Voucher in December 2025 and is in regulatory filing discussions. If approved, enlicitide would extend the macrocyclic peptide playbook into cardiovascular disease at massive scale.

Looking across the PDC landscape, the clinical drugs are less interesting than the platforms that produce them. The leading platforms differ sharply in how they generate candidate peptides:

• Bicycle's bicyclic peptide phage display uses engineered bacteriophage libraries to present constrained dual-loop peptides. The constraint is structural — chemical cross-links lock the peptide into antibody-like conformations while preserving small-molecule PK. Every Bicycle drug inherits fast renal clearance and deep tumor penetration.
• PeptiDream's PDPS uses mRNA display of libraries incorporating non-standard amino acids (genetically expanded codons). This produces macrocyclic peptides with unusual backbones that are resistant to proteolysis and often orally bioavailable.
• Circle Pharma's macrocyclic peptide library is a rational-design approach — structures are designed in silico to disrupt specific protein-protein interactions, then synthesized and screened. The target set is intentionally focused on intracellular PPIs considered undruggable by small molecules or biologics.
• Sapience's SPEAR platform focuses on cell-penetrating peptides that disrupt intracellular transcription factor interactions. ST316 is the proof-of-concept that transcription factors can be drugged.
• Syneron Bio's Synova is an AI-driven macrocyclic peptide discovery platform based in Beijing. Syneron closed a $150M Series B on March 31, 2026 — just four months after its $100M Series A — and has a March 2025 strategic collaboration with AstraZeneca worth up to $3.4B in milestones. The AstraZeneca deal is a signal that Western pharma sees competitive peptide discovery capacity outside the US and Japan.
• Novartis's radioligand platform is different — it's vertically integrated rather than discovery-focused. Through Advanced Accelerator Applications (acquired 2018), Endocyte (2018), and Mariana Oncology (2024), Novartis controls discovery, isotope supply, manufacturing (Ivrea, Millburn, Indianapolis), and a network of 670+ US specialty treatment centers. No competitor has this end-to-end infrastructure.

Per the PDCdb database, 78% of PDCs entering clinical trials since 2022 used AI-optimized components, compared to less than 15% before 2020. AI is accelerating peptide discovery across all platforms — predicting target binding, structural stability, and pharmacokinetics computationally rather than through exhaustive wet-lab screening.

Four problems stand between PDCs' current footprint and the projected $1.5B+ market by 2031.

Half-life and kidney exposure come first. Peptides clear through the kidneys. For radioligands, that concentrates isotope in renal tubules. Long-term follow-up of 177Lu-PSMA-617 patients (2025 EJNMMI data) shows measurable CKD-EPI declines correlating with cumulative kidney dose. Bone marrow toxicity is the leading adverse event for both approved radio-PDCs, and it worsens in renal impairment as slower excretion extends marrow exposure. EANM now recommends individualized dosimetry for every patient — a logistical burden that limits how fast treatment centers can scale throughput.

Isotope supply and logistics are the second. Actinium-225 production is measured in gigabequerels globally per year, enough for maybe a few thousand doses. Lead-212's 10.6-hour half-life requires point-of-use generators. Lutetium-177 supply has scaled but still constrains growth. Novartis is expanding manufacturing — its Indianapolis facility came online in 2023 and added 250 batches per week of capacity — and Orano Med's Plano, Texas facility focuses on Pb-212. These are multi-hundred-million-dollar investments with multi-year lead times.

Reimbursement and specialty center concentration are the third. Pluvicto costs ~$42,000 per cycle, with patients typically receiving six cycles. Even with Medicare Part B coverage and manufacturer patient assistance, the out-of-pocket burden is significant. The therapy requires specialty cold-chain logistics, nuclear medicine certification, and an infusion suite with radioactive waste handling — infrastructure that doesn't exist in every oncology practice. The US has 670 active Pluvicto treatment centers as of 2025, with uneven geographic coverage.

Manufacturing at scale is the fourth, particularly for macrocyclic peptides. Cyclization is the hardest step in solid-phase peptide synthesis, and yield losses compound with each additional cycle or modification. Analytics for conjugates over 2 kDa complicate mass spectrometry and QC. Companies with proprietary conjugation chemistry (Bicycle's bicycle-formation, PeptiDream's mRNA display with non-canonical amino acids) have moats here, but scaling those processes from clinical to commercial batches is an open question.

The next 12-18 months will likely define which PDC platforms survive and which stall.

Pluvicto mHSPC filing (2H 2026) is the biggest near-term catalyst. If approved, Pluvicto enters the hormone-sensitive prostate cancer setting and potentially triples the market again.

Perspective Therapeutics' Phase 1/2a full readout is the alpha-emitter swing factor. If the 43% ORR interim holds across the full cohort, Perspective becomes a credible alpha-emitter competitor to Novartis.

Bicycle Therapeutics' Duravelo-2 readout will determine whether zelenectide pevedotin can compete with Padcev (enfortumab vedotin) in urothelial cancer.

Circle Pharma's CID-078 expansion cohorts will test whether the RB1-altered sarcoma response generalizes — the Phase 1 signal is hypothesis-generating, and dose-expansion data will tell.

Merck's enlicitide decanoate regulatory submission would mark the first oral macrocyclic peptide to reach the market. If approved, it would reshape cardiovascular drug development and validate peptide-based oral therapies far beyond oncology.

Alpha-emitter supply capacity is the wildcard. Any announcement from Novartis, Orano Med, or a new entrant about scaling Ac-225 or Pb-212 production would directly translate into patient access.

The quiet revolution in PDCs has been building for two decades — from early peptide drug designs in the 1990s, through Lutathera's 2018 approval, to the radioligand commercial breakout of 2024-2025. The current pipeline suggests the next phase will be broader (cytotoxic PDCs outside radioligand therapy), deeper (more validated targets beyond SSTR2 and PSMA), and more diverse (autoimmune disease, cardiovascular disease) than anything the market has seen before.